Merck agrees to buy cancer drugmaker Terns for $53 per share
MLex Summary: Merck intends to acquire oncology medicine creator Terns Pharmaceuticals for approximately $6.7 billion in equity value, or $53 a share, according to a corporate press release. Terns has a...To view the full article, register now.
Already a subscriber? Click here to view full article